Edition:
United States

Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

67.00SEK
24 May 2017
Change (% chg)

-1.00kr (-1.47%)
Prev Close
68.00kr
Open
68.00kr
Day's High
68.00kr
Day's Low
67.00kr
Volume
2,324
Avg. Vol
63,106
52-wk High
102.00kr
52-wk Low
48.20kr

Latest Key Developments (Source: Significant Developments)

Medivir Q1 operating loss widens
Friday, 28 Apr 2017 02:30am EDT 

April 28 (Reuters) - Medivir :Q1 net turnover for continuing operations SEK 17.8 million (20.6), SEK 13.7 million (18.1) of which comprised Q1's royalties for simeprevir.Q1 loss before interest, tax, depreciation and amortisation (EBITDA) SEK -80.9 million (-60.7).Q1 cash flow from operating activities SEK -123.9 million (-36.4).Q1 cash and cash equivalents at period end SEK 708.9 million (1,039.5).  Full Article

Medivir starts new combination study on simeprevir
Monday, 24 Apr 2017 02:30am EDT 

April 24 (Reuters) - Medivir AB :Update on the development of simeprevir as part of the triple combination with al-335 and odalasvir (jnj-4178).Says data from an ongoing phase II study demonstrate that this regimen has the potential to shorten treatment duration, offer high efficacy and is generally well tolerated in those whose disease is caused by hepatitis C virus (HCV) genotype 1 (GT1), one of the most prevalent causes of hepatitis C globally.Says enrolment has recently been completed into the global phase IIb OMEGA-1 study of JNJ-4178. This open-label study is assessing the efficacy and safety of JNJ-4178 in non-cirrhotic patients with HCV genotypes 1, 2, 4, 5 and 6.  Full Article

Medivir announces positive phase II study data, shares rise
Friday, 7 Apr 2017 02:30am EDT 

Medivir AB : Says announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma . Says based on these data, Medivir expects to initiate discussions with regulatory authorities with the aim of initiating a phase III study later this year, and to present full phase II trial data at scientific meetings in the second half of 2017 .Medivir shares rise 5 pct at 10:36 GMT, on the way to the strongest daily performance in 2017.  Full Article

Medivir says completes transition of commercial products
Thursday, 16 Mar 2017 03:30am EDT 

Medivir : Medivir completes transition of commercial products to fully focus on research and development . Says has come to agreement with Janssen to outlicense commercial rights to nordics for simeprevir and future simeprevir containing products . Medivir will receive royalties on sales of all simeprevir containing products in the Nordics, as it already does in the rest of the world, and additional performance based milestones totaling up to approximately 6 MEUR based on certain sales targets for the Nordics of a combination product containing simeprevir .Additionally, Medivir has returned the commercial rights to Adasuve in the Nordic region to Ferrer, the market authorization holder of that product.  Full Article

Medivir says executive management team members increase holdings
Friday, 17 Feb 2017 07:15am EST 

Medivir : Executive management team members increase their holdings in Medivir . Says departing CEO Niklas Prager, CEO designate Christine Lind and CFO Ola Burmark today have bought a total of 16.500 shares in Medivir .Says purchase was made simultaneously with their sale of a total of 52.101 redemption rights, which were received in connection with ongoing voluntary redemption program.  Full Article

Medivir Q4 loss after tax widens
Friday, 17 Feb 2017 02:30am EST 

Medivir : Q4 net turnover for continuing operations totalled SEK 9.9 million (34.5 m), SEK 5.6 million (31.1 m) of which comprised royalties for Simeprevir . Q4 profit after tax for continuing operations was SEK -121.3 million (-56.9 m) .Says we also reorganised company's early stage research and administrative functions during quarter. It is estimated that this will give annual savings totalling approximately SEK 110 million.  Full Article

Medivir says EGM backs redemption programme
Thursday, 2 Feb 2017 09:48am EST 

Medivir Ab : Medivir says egm resolved on a voluntary redemption programme comprising reduction of share capital for repayment to shareholders and bonus issue without issuance of new shares . redemption programme will be effected by redemption of a maximum of 6,738,655 shares, whereof 151,589 series A shares and 6,587,066 series B shares . The company shall pay an amount of SEK 129 for each share redeemed .The reduction is made by way of repayment to the shareholders with a maximum amount of SEK 869,286,495..  Full Article

Medivir continues osteoarthritis trial after third review
Thursday, 8 Dec 2016 02:30am EST 

Medivir Ab : Medivir says MIV-711 osteoarthritis trial: successful third independent review of safety data and trial continues without any modifications .Says it is expected that data from MIV-711-201 will be available in the third quarter of 2017 and that data from the extension study will be available in the first half of 2018.  Full Article

Medivir says phase IIa data shows high level of efficacy for liver drugs
Friday, 23 Sep 2016 11:56am EDT 

Medivir Ab Updated interim phase IIa data demonstrate that the combination of simeprevir, odalasvir and AL-335 has a high level of efficacy in HCV patients:.  Full Article

Medivir: recommendation to go ahead in MIV-711 osteoarthritis trial
Friday, 23 Sep 2016 02:30am EDT 

Medivir Ab : MIV-711 osteoarthritis trial: recommendation to go ahead based on independent review of safety data, and first patient enrolled in extension study . It is expected that data from MIV-711-201 will be available in the second half of 2017 and that data from the extension study will be available in the first half of 2018 Further company coverage: [MVIRb.ST].  Full Article

More From Around the Web

BRIEF-Medivir Q1 operating loss widens

* Q1 net turnover for continuing operations SEK 17.8 million (20.6), SEK 13.7 million (18.1) of which comprised Q1's royalties for simeprevir